McDonnell Boehnen Hulbert & Berghoff LLP partner Paul H. Berghoff is quoted extensively in a March 26, 2013 Investor’s Business Daily article entitled, “‘Pay for Delay’ Case Could Change Generic Drug Rules.” Mr. Berghoff was interviewed in light of the U.S. Supreme Court this week hearing arguments in a case that could change the dynamics in the tug-of-war between drug developers and makers of generic knockoffs. He spoke with Investor’s Business Daily about the issues at stake in FTC vs. Actavis and what it could mean for the industry.
View the article